Scilex and Oracle: Bullish Views, Potential Upsides Unveiled
- October 09th, 2023
- 665 views
HC Wainwright & Co. has initiated coverage on Scilex Holding Company (Nasdaq: SCLX), a pharmaceutical company, with a Buy rating and a price target of $12.
Closing at $1.57 on Friday, this price target suggests a substantial potential upside of $10.43 per share or approximately 664.33% for $SCLX, based on the financial services firm's view.
Separately, Evercore ISI Group upgraded Oracle Corporation (NYSE: ORCL), a multinational technology company, from In-Line to Outperform and raised the price target from $131 to $135.
With $ORCL closing at $109.96 on Friday, the projected new price target implies a potential upside of $25.04 per share or about 22.77%, according to the investment banking advisory firm's assessment.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025
Member Login